SPIRITT Research Becomes Latest CRO to Join MedNet Solutions' iMedNet Partner Program
SPIRITT Selects iMedNet EDC for its eClinical Flexibility and Ease of Use
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that SPIRITT Research, a boutique research services organization with a passion for improving patient treatment outcomes and quality of life, has joined MedNet’s iMedNet Partner Program. SPIRITT will leverage iMedNet EDC, MedNet’s flagship eClinical solution, to get their research studies set up quickly, easily and cost-effectively.
“SPIRITT is an ideal partner for MedNet, given our companies’ deep, shared expertise supporting orthopedic and spine related research, as well as post market studies and registries,” remarked John M. (Rob) Robertson, President and CEO of MedNet Solutions. “We’re confident that our organizations will work very well together and that iMedNet EDC will provide SPIRITT with the technology infrastructure they need to facilitate effective and efficient research.”
“We are very pleased to be partnering with MedNet Solutions,” commented Francine Schranck, President of SPIRITT. “The iMedNet product is one of the best clinical trial management systems we’ve seen, and we recommend it without reservation.”
Matthew Britt, Director of Clinical Affairs at SPIRITT, added, “We are asked all the time by our clients about the best solutions to support them in their various clinical trials, and because of its flexibility and ease of use, iMedNet is a logical choice.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
